Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pulmonary Disease, Chronic Obstructive | 101 | 2024 | 247 | 20.050 |
Why?
|
Asthma | 111 | 2024 | 955 | 16.190 |
Why?
|
Anti-Asthmatic Agents | 25 | 2023 | 76 | 4.610 |
Why?
|
Comparative Effectiveness Research | 12 | 2018 | 53 | 4.050 |
Why?
|
Adrenal Cortex Hormones | 29 | 2024 | 263 | 3.780 |
Why?
|
Oxygen Inhalation Therapy | 13 | 2023 | 60 | 3.650 |
Why?
|
Patient Readmission | 8 | 2023 | 329 | 2.830 |
Why?
|
Hospitalization | 28 | 2024 | 849 | 2.660 |
Why?
|
Humans | 312 | 2024 | 86643 | 2.540 |
Why?
|
Models, Biological | 15 | 2016 | 1749 | 2.360 |
Why?
|
Practice Guidelines as Topic | 25 | 2022 | 1036 | 2.210 |
Why?
|
Signal Transduction | 13 | 2016 | 3241 | 2.190 |
Why?
|
Forced Expiratory Volume | 30 | 2023 | 122 | 2.030 |
Why?
|
Evidence-Based Medicine | 11 | 2021 | 429 | 1.970 |
Why?
|
Administration, Inhalation | 30 | 2024 | 188 | 1.880 |
Why?
|
Delivery of Health Care | 6 | 2022 | 426 | 1.840 |
Why?
|
United States | 68 | 2024 | 6672 | 1.840 |
Why?
|
Muscarinic Antagonists | 5 | 2022 | 55 | 1.830 |
Why?
|
Patient Discharge | 12 | 2022 | 300 | 1.810 |
Why?
|
Patient Education as Topic | 8 | 2017 | 351 | 1.800 |
Why?
|
Bronchodilator Agents | 17 | 2024 | 65 | 1.800 |
Why?
|
Research Design | 15 | 2022 | 594 | 1.720 |
Why?
|
Home Care Services | 5 | 2020 | 72 | 1.680 |
Why?
|
Spirometry | 18 | 2023 | 66 | 1.620 |
Why?
|
Glucocorticoids | 9 | 2022 | 352 | 1.560 |
Why?
|
Disease Progression | 28 | 2024 | 1531 | 1.520 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 9 | 2024 | 23 | 1.510 |
Why?
|
Pulmonary Medicine | 9 | 2020 | 46 | 1.470 |
Why?
|
Smoking | 16 | 2023 | 609 | 1.440 |
Why?
|
Patient Outcome Assessment | 8 | 2022 | 84 | 1.430 |
Why?
|
Chemotaxis | 6 | 2010 | 72 | 1.420 |
Why?
|
Middle Aged | 113 | 2024 | 25028 | 1.420 |
Why?
|
Critical Care | 8 | 2021 | 370 | 1.410 |
Why?
|
Lung | 21 | 2023 | 1170 | 1.400 |
Why?
|
Male | 143 | 2024 | 40965 | 1.400 |
Why?
|
Adult | 103 | 2024 | 25648 | 1.390 |
Why?
|
Quality of Life | 21 | 2023 | 1585 | 1.360 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2022 | 865 | 1.360 |
Why?
|
Female | 143 | 2024 | 44532 | 1.350 |
Why?
|
Biomedical Research | 3 | 2023 | 376 | 1.320 |
Why?
|
Vital Capacity | 15 | 2023 | 64 | 1.300 |
Why?
|
Air Pollution, Indoor | 6 | 2023 | 63 | 1.270 |
Why?
|
Emergency Service, Hospital | 10 | 2017 | 484 | 1.270 |
Why?
|
Computer Simulation | 8 | 2016 | 1078 | 1.220 |
Why?
|
Metered Dose Inhalers | 4 | 2019 | 33 | 1.160 |
Why?
|
Severity of Illness Index | 28 | 2022 | 1801 | 1.150 |
Why?
|
Enzymes | 3 | 2014 | 47 | 1.130 |
Why?
|
Aged | 79 | 2023 | 18415 | 1.120 |
Why?
|
Observational Studies as Topic | 4 | 2023 | 48 | 1.110 |
Why?
|
Smokers | 7 | 2023 | 41 | 1.040 |
Why?
|
Oxygen | 6 | 2024 | 726 | 1.040 |
Why?
|
Hypoxia | 6 | 2021 | 641 | 0.930 |
Why?
|
Natural Gas | 1 | 2023 | 2 | 0.930 |
Why?
|
Budesonide | 4 | 2024 | 45 | 0.900 |
Why?
|
Pulmonary Emphysema | 5 | 2022 | 30 | 0.900 |
Why?
|
Sleep Wake Disorders | 7 | 2022 | 115 | 0.900 |
Why?
|
Patient Compliance | 9 | 2023 | 227 | 0.890 |
Why?
|
Dictyostelium | 3 | 2010 | 43 | 0.890 |
Why?
|
Nebulizers and Vaporizers | 5 | 2023 | 55 | 0.880 |
Why?
|
Systems Biology | 4 | 2016 | 42 | 0.880 |
Why?
|
Lung Diseases | 10 | 2023 | 263 | 0.870 |
Why?
|
Child | 34 | 2023 | 6927 | 0.860 |
Why?
|
Emergency Medical Services | 3 | 2009 | 209 | 0.860 |
Why?
|
Biomarkers | 18 | 2023 | 1718 | 0.840 |
Why?
|
Telephone | 1 | 2021 | 32 | 0.830 |
Why?
|
Clinical Trials as Topic | 6 | 2018 | 1169 | 0.830 |
Why?
|
Healthcare Disparities | 6 | 2021 | 371 | 0.820 |
Why?
|
Cohort Studies | 25 | 2024 | 2767 | 0.820 |
Why?
|
Telemedicine | 2 | 2022 | 169 | 0.820 |
Why?
|
Societies | 1 | 2021 | 12 | 0.820 |
Why?
|
Bronchial Thermoplasty | 1 | 2021 | 6 | 0.790 |
Why?
|
Social Isolation | 1 | 2021 | 67 | 0.790 |
Why?
|
Registries | 4 | 2021 | 702 | 0.780 |
Why?
|
Thoracic Diseases | 1 | 2021 | 25 | 0.780 |
Why?
|
Respiratory Insufficiency | 3 | 2019 | 150 | 0.770 |
Why?
|
Venous Thrombosis | 7 | 2023 | 243 | 0.770 |
Why?
|
Communicable Disease Control | 1 | 2021 | 51 | 0.770 |
Why?
|
Immunization | 1 | 2021 | 158 | 0.770 |
Why?
|
Prospective Studies | 28 | 2023 | 4213 | 0.750 |
Why?
|
Models, Molecular | 2 | 2016 | 1286 | 0.750 |
Why?
|
Self Care | 8 | 2022 | 164 | 0.750 |
Why?
|
Communicable Diseases | 1 | 2021 | 63 | 0.740 |
Why?
|
Surveys and Questionnaires | 20 | 2022 | 2501 | 0.730 |
Why?
|
Data Collection | 3 | 2019 | 372 | 0.720 |
Why?
|
Depression | 9 | 2022 | 473 | 0.720 |
Why?
|
Phosphoric Monoester Hydrolases | 2 | 2013 | 51 | 0.720 |
Why?
|
Vaccines | 1 | 2021 | 80 | 0.720 |
Why?
|
Respiratory Function Tests | 12 | 2023 | 136 | 0.710 |
Why?
|
Clinical Decision-Making | 2 | 2021 | 257 | 0.700 |
Why?
|
Patient-Centered Care | 4 | 2016 | 203 | 0.690 |
Why?
|
Airway Obstruction | 3 | 2022 | 109 | 0.690 |
Why?
|
Anti-Bacterial Agents | 5 | 2022 | 746 | 0.680 |
Why?
|
Health Services Accessibility | 5 | 2023 | 394 | 0.680 |
Why?
|
Urban Population | 8 | 2021 | 213 | 0.660 |
Why?
|
Eosinophils | 6 | 2023 | 194 | 0.660 |
Why?
|
Aged, 80 and over | 31 | 2021 | 6509 | 0.650 |
Why?
|
Inpatients | 3 | 2012 | 297 | 0.650 |
Why?
|
Software | 2 | 2021 | 654 | 0.640 |
Why?
|
Continuity of Patient Care | 3 | 2009 | 169 | 0.630 |
Why?
|
Risk Assessment | 11 | 2020 | 2261 | 0.630 |
Why?
|
Cross-Sectional Studies | 20 | 2021 | 1621 | 0.620 |
Why?
|
Activities of Daily Living | 7 | 2014 | 204 | 0.600 |
Why?
|
Natural Language Processing | 1 | 2017 | 37 | 0.590 |
Why?
|
Treatment Outcome | 25 | 2023 | 7993 | 0.590 |
Why?
|
Adolescent | 27 | 2023 | 8981 | 0.580 |
Why?
|
Drug Therapy, Combination | 11 | 2022 | 894 | 0.580 |
Why?
|
Anti-Inflammatory Agents | 2 | 2009 | 339 | 0.580 |
Why?
|
Respiratory System Agents | 1 | 2016 | 7 | 0.570 |
Why?
|
Thromboembolism | 4 | 2006 | 119 | 0.570 |
Why?
|
Eosinophilia | 4 | 2023 | 84 | 0.570 |
Why?
|
Formoterol Fumarate | 7 | 2024 | 8 | 0.570 |
Why?
|
Fluticasone | 4 | 2021 | 30 | 0.570 |
Why?
|
Acute Disease | 9 | 2018 | 826 | 0.560 |
Why?
|
Societies, Medical | 12 | 2021 | 572 | 0.560 |
Why?
|
Retrospective Studies | 24 | 2024 | 8489 | 0.550 |
Why?
|
Health Services Research | 2 | 2021 | 136 | 0.540 |
Why?
|
Practice Patterns, Physicians' | 3 | 2019 | 582 | 0.540 |
Why?
|
Anticoagulants | 6 | 2023 | 408 | 0.530 |
Why?
|
Cell Compartmentation | 1 | 2015 | 69 | 0.530 |
Why?
|
Patient Care Bundles | 1 | 2015 | 20 | 0.530 |
Why?
|
Sleep Medicine Specialty | 4 | 2018 | 9 | 0.530 |
Why?
|
Transitional Care | 3 | 2021 | 18 | 0.520 |
Why?
|
Chicago | 8 | 2022 | 1379 | 0.520 |
Why?
|
Perception | 3 | 2019 | 168 | 0.510 |
Why?
|
Algorithms | 6 | 2013 | 1830 | 0.510 |
Why?
|
Cell Membrane | 2 | 2009 | 666 | 0.500 |
Why?
|
Biological Clocks | 1 | 2015 | 74 | 0.500 |
Why?
|
Environmental Exposure | 6 | 2022 | 296 | 0.500 |
Why?
|
Methylprednisolone | 1 | 2014 | 66 | 0.490 |
Why?
|
Advisory Committees | 5 | 2021 | 90 | 0.490 |
Why?
|
Patient Participation | 2 | 2016 | 216 | 0.490 |
Why?
|
Hospital Mortality | 5 | 2013 | 349 | 0.480 |
Why?
|
Primary Health Care | 4 | 2023 | 339 | 0.480 |
Why?
|
Smoking Cessation | 3 | 2016 | 230 | 0.480 |
Why?
|
Minority Groups | 3 | 2021 | 137 | 0.480 |
Why?
|
Cell Cycle | 1 | 2016 | 502 | 0.470 |
Why?
|
Exercise Therapy | 1 | 2014 | 80 | 0.470 |
Why?
|
Phosphotransferases | 1 | 2013 | 65 | 0.470 |
Why?
|
Energy Intake | 2 | 2004 | 98 | 0.460 |
Why?
|
Child, Preschool | 15 | 2022 | 3612 | 0.460 |
Why?
|
Fracture Fixation | 2 | 2003 | 31 | 0.460 |
Why?
|
Air Pollutants | 3 | 2022 | 78 | 0.450 |
Why?
|
International Classification of Diseases | 3 | 2016 | 69 | 0.450 |
Why?
|
Chronic Disease | 8 | 2022 | 971 | 0.450 |
Why?
|
Sputum | 7 | 2023 | 34 | 0.450 |
Why?
|
Radius Fractures | 2 | 2003 | 30 | 0.450 |
Why?
|
Quality of Health Care | 5 | 2023 | 380 | 0.440 |
Why?
|
Protein Processing, Post-Translational | 1 | 2015 | 371 | 0.440 |
Why?
|
Ophthalmology | 2 | 2023 | 39 | 0.440 |
Why?
|
Length of Stay | 8 | 2021 | 702 | 0.440 |
Why?
|
Reproducibility of Results | 7 | 2021 | 2705 | 0.440 |
Why?
|
Patient Care Management | 1 | 2012 | 31 | 0.440 |
Why?
|
Motor Activity | 2 | 2014 | 327 | 0.440 |
Why?
|
Dyspnea | 6 | 2023 | 73 | 0.420 |
Why?
|
Research Support as Topic | 2 | 2011 | 80 | 0.420 |
Why?
|
Comorbidity | 8 | 2022 | 943 | 0.420 |
Why?
|
Precision Medicine | 3 | 2021 | 395 | 0.420 |
Why?
|
Chest Wall Oscillation | 1 | 2011 | 5 | 0.410 |
Why?
|
Disease Management | 8 | 2021 | 327 | 0.410 |
Why?
|
Clinical Coding | 1 | 2011 | 23 | 0.400 |
Why?
|
Diffusion of Innovation | 2 | 2016 | 71 | 0.400 |
Why?
|
Ozone | 2 | 2022 | 8 | 0.400 |
Why?
|
Allosteric Regulation | 1 | 2011 | 68 | 0.400 |
Why?
|
Delivery of Health Care, Integrated | 3 | 2018 | 57 | 0.400 |
Why?
|
Medicare | 4 | 2023 | 410 | 0.390 |
Why?
|
Housing | 3 | 2022 | 42 | 0.390 |
Why?
|
Salmeterol Xinafoate | 2 | 2021 | 16 | 0.390 |
Why?
|
Critical Illness | 3 | 2016 | 294 | 0.390 |
Why?
|
Caregivers | 5 | 2016 | 151 | 0.390 |
Why?
|
Academic Medical Centers | 2 | 2011 | 379 | 0.390 |
Why?
|
Health Status Indicators | 4 | 2014 | 105 | 0.390 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2010 | 28 | 0.380 |
Why?
|
Allergens | 3 | 2006 | 179 | 0.380 |
Why?
|
Respiratory Tract Diseases | 3 | 2013 | 45 | 0.380 |
Why?
|
Knowledge | 1 | 2010 | 29 | 0.380 |
Why?
|
Health Care Costs | 2 | 2018 | 238 | 0.380 |
Why?
|
Equipment Failure | 1 | 2011 | 119 | 0.380 |
Why?
|
Shoulder Impingement Syndrome | 2 | 2000 | 2 | 0.370 |
Why?
|
Prevalence | 8 | 2020 | 1239 | 0.370 |
Why?
|
Tiotropium Bromide | 3 | 2019 | 4 | 0.360 |
Why?
|
Air Pollution | 2 | 2022 | 68 | 0.360 |
Why?
|
Patient Safety | 2 | 2023 | 212 | 0.360 |
Why?
|
Quality Assurance, Health Care | 5 | 2021 | 220 | 0.350 |
Why?
|
Guideline Adherence | 5 | 2019 | 223 | 0.350 |
Why?
|
Aspirin | 2 | 2021 | 156 | 0.340 |
Why?
|
Warfarin | 3 | 2013 | 103 | 0.340 |
Why?
|
Health Status Disparities | 2 | 2021 | 170 | 0.340 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 379 | 0.340 |
Why?
|
Teaching | 1 | 2010 | 147 | 0.340 |
Why?
|
Appointments and Schedules | 1 | 2009 | 53 | 0.340 |
Why?
|
Logistic Models | 12 | 2021 | 1186 | 0.340 |
Why?
|
Emergency Medicine | 1 | 2010 | 123 | 0.340 |
Why?
|
Risk Factors | 19 | 2022 | 5417 | 0.340 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2010 | 262 | 0.330 |
Why?
|
Recurrence | 5 | 2011 | 1139 | 0.330 |
Why?
|
Continuous Positive Airway Pressure | 3 | 2017 | 53 | 0.330 |
Why?
|
Social Class | 4 | 2021 | 128 | 0.330 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 316 | 0.320 |
Why?
|
Medication Adherence | 4 | 2019 | 129 | 0.320 |
Why?
|
Tomography, X-Ray Computed | 12 | 2021 | 2601 | 0.320 |
Why?
|
Pregnancy Complications | 3 | 2021 | 336 | 0.320 |
Why?
|
Control Groups | 1 | 2007 | 15 | 0.320 |
Why?
|
Respiratory Hypersensitivity | 1 | 2007 | 41 | 0.310 |
Why?
|
Longitudinal Studies | 10 | 2023 | 1019 | 0.310 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 3 | 2016 | 21 | 0.310 |
Why?
|
Pulmonary Embolism | 4 | 2004 | 222 | 0.310 |
Why?
|
Pandemics | 3 | 2022 | 740 | 0.310 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2004 | 29 | 0.300 |
Why?
|
Patient Care Planning | 2 | 2005 | 81 | 0.300 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2012 | 1373 | 0.300 |
Why?
|
Interviews as Topic | 4 | 2016 | 319 | 0.300 |
Why?
|
Social Support | 2 | 2021 | 193 | 0.300 |
Why?
|
Drug Costs | 1 | 2007 | 62 | 0.300 |
Why?
|
Pest Control | 2 | 2006 | 6 | 0.290 |
Why?
|
Double-Blind Method | 9 | 2023 | 1823 | 0.290 |
Why?
|
Socioeconomic Factors | 7 | 2021 | 567 | 0.290 |
Why?
|
Pneumonia, Bacterial | 1 | 2006 | 28 | 0.280 |
Why?
|
Vitamin D Deficiency | 2 | 2020 | 103 | 0.280 |
Why?
|
Feedback, Physiological | 3 | 2011 | 62 | 0.280 |
Why?
|
Cell Polarity | 1 | 2006 | 115 | 0.280 |
Why?
|
Obesity | 5 | 2023 | 963 | 0.280 |
Why?
|
Environmental Health | 1 | 2005 | 7 | 0.270 |
Why?
|
Mechanotransduction, Cellular | 1 | 2006 | 77 | 0.270 |
Why?
|
Health Status | 4 | 2016 | 360 | 0.270 |
Why?
|
Preventive Medicine | 1 | 2005 | 17 | 0.270 |
Why?
|
Adrenergic beta-Agonists | 3 | 2011 | 72 | 0.270 |
Why?
|
Phosphatidylinositols | 1 | 2005 | 21 | 0.270 |
Why?
|
Electronic Health Records | 3 | 2021 | 319 | 0.270 |
Why?
|
Venous Thromboembolism | 2 | 2023 | 153 | 0.270 |
Why?
|
Lung Transplantation | 5 | 2010 | 175 | 0.270 |
Why?
|
Child Welfare | 1 | 2005 | 39 | 0.270 |
Why?
|
Follow-Up Studies | 10 | 2023 | 3640 | 0.260 |
Why?
|
Health Expenditures | 2 | 2016 | 86 | 0.260 |
Why?
|
Receptors, Cell Surface | 1 | 2006 | 286 | 0.260 |
Why?
|
Mucus | 2 | 2023 | 19 | 0.260 |
Why?
|
Immunoglobulin E | 3 | 2020 | 144 | 0.260 |
Why?
|
Cost-Benefit Analysis | 4 | 2019 | 454 | 0.260 |
Why?
|
Hypersensitivity, Immediate | 2 | 2020 | 62 | 0.250 |
Why?
|
Educational Status | 1 | 2005 | 188 | 0.250 |
Why?
|
Leukocyte Count | 6 | 2019 | 220 | 0.250 |
Why?
|
Patient Transfer | 3 | 2016 | 91 | 0.250 |
Why?
|
Sex Factors | 2 | 2016 | 1054 | 0.250 |
Why?
|
Multivariate Analysis | 8 | 2017 | 999 | 0.250 |
Why?
|
Isoenzymes | 1 | 2005 | 271 | 0.250 |
Why?
|
Chemotactic Factors | 1 | 2004 | 14 | 0.250 |
Why?
|
Age Factors | 6 | 2022 | 1851 | 0.250 |
Why?
|
Young Adult | 13 | 2022 | 5976 | 0.250 |
Why?
|
Membrane Lipids | 1 | 2004 | 40 | 0.250 |
Why?
|
Education | 3 | 2018 | 58 | 0.250 |
Why?
|
Pragmatic Clinical Trials as Topic | 2 | 2014 | 4 | 0.250 |
Why?
|
Insurance | 1 | 2024 | 11 | 0.240 |
Why?
|
Chemoreceptor Cells | 1 | 2004 | 65 | 0.240 |
Why?
|
Patient Reported Outcome Measures | 2 | 2022 | 166 | 0.240 |
Why?
|
Hemorrhage | 2 | 2023 | 268 | 0.240 |
Why?
|
Fractures, Comminuted | 1 | 2003 | 5 | 0.240 |
Why?
|
Ventilator Weaning | 1 | 2004 | 24 | 0.240 |
Why?
|
External Fixators | 1 | 2003 | 19 | 0.240 |
Why?
|
Hypertension, Pulmonary | 2 | 2005 | 346 | 0.240 |
Why?
|
Neoplasms | 5 | 2022 | 2898 | 0.230 |
Why?
|
Hand Strength | 2 | 2003 | 51 | 0.230 |
Why?
|
Biocatalysis | 2 | 2014 | 51 | 0.230 |
Why?
|
Antibodies, Monoclonal | 2 | 2007 | 1376 | 0.230 |
Why?
|
Tumor Suppressor Proteins | 1 | 2005 | 279 | 0.230 |
Why?
|
Thrombophilia | 1 | 2003 | 22 | 0.230 |
Why?
|
Mucins | 1 | 2023 | 39 | 0.230 |
Why?
|
Intensive Care Units | 2 | 2004 | 373 | 0.230 |
Why?
|
Sleep Apnea, Obstructive | 3 | 2018 | 219 | 0.230 |
Why?
|
Information Systems | 2 | 2021 | 29 | 0.230 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2021 | 134 | 0.230 |
Why?
|
Linear Models | 4 | 2017 | 421 | 0.230 |
Why?
|
Cigarette Smoking | 1 | 2023 | 30 | 0.230 |
Why?
|
Infant | 4 | 2022 | 3046 | 0.220 |
Why?
|
Bone Nails | 1 | 2002 | 17 | 0.220 |
Why?
|
Pneumococcal Infections | 1 | 2023 | 46 | 0.220 |
Why?
|
United Kingdom | 2 | 2019 | 164 | 0.220 |
Why?
|
Models, Theoretical | 3 | 2015 | 482 | 0.220 |
Why?
|
Databases, Factual | 4 | 2019 | 814 | 0.220 |
Why?
|
Overweight | 1 | 2023 | 118 | 0.220 |
Why?
|
Eukaryotic Cells | 1 | 2003 | 43 | 0.220 |
Why?
|
Food Supply | 1 | 2022 | 28 | 0.220 |
Why?
|
Symptom Flare Up | 2 | 2020 | 11 | 0.220 |
Why?
|
Symptom Assessment | 3 | 2019 | 65 | 0.220 |
Why?
|
Bone Diseases, Metabolic | 1 | 2002 | 33 | 0.220 |
Why?
|
Cooking | 1 | 2023 | 55 | 0.220 |
Why?
|
Respiratory Mucosa | 2 | 2021 | 88 | 0.220 |
Why?
|
Cross Infection | 1 | 2004 | 141 | 0.220 |
Why?
|
Time | 2 | 2019 | 77 | 0.220 |
Why?
|
Anemia, Sickle Cell | 1 | 2004 | 131 | 0.210 |
Why?
|
Hospitals, Teaching | 3 | 2023 | 115 | 0.210 |
Why?
|
Time Factors | 11 | 2019 | 5210 | 0.210 |
Why?
|
Social Segregation | 1 | 2021 | 3 | 0.210 |
Why?
|
Odds Ratio | 5 | 2016 | 678 | 0.210 |
Why?
|
Phosphorylation | 2 | 2015 | 1106 | 0.200 |
Why?
|
Factor Xa Inhibitors | 1 | 2021 | 22 | 0.200 |
Why?
|
Health Facilities | 1 | 2021 | 38 | 0.200 |
Why?
|
Self Report | 2 | 2022 | 288 | 0.200 |
Why?
|
Information Dissemination | 2 | 2014 | 103 | 0.200 |
Why?
|
Space Perception | 1 | 2003 | 115 | 0.200 |
Why?
|
Pyridones | 1 | 2021 | 51 | 0.200 |
Why?
|
Government Programs | 2 | 2022 | 8 | 0.200 |
Why?
|
Secondary Prevention | 2 | 2017 | 162 | 0.200 |
Why?
|
Respiratory Care Units | 3 | 2009 | 4 | 0.200 |
Why?
|
Bronchoscopy | 2 | 2013 | 152 | 0.200 |
Why?
|
Hospitals | 2 | 2022 | 294 | 0.200 |
Why?
|
Causality | 1 | 2021 | 81 | 0.200 |
Why?
|
Arthroplasty, Replacement, Knee | 2 | 2004 | 111 | 0.200 |
Why?
|
Muscarinic Agonists | 1 | 2020 | 23 | 0.200 |
Why?
|
Lactation | 1 | 2021 | 53 | 0.190 |
Why?
|
Observer Variation | 3 | 2018 | 602 | 0.190 |
Why?
|
Pharmacogenomic Testing | 1 | 2021 | 97 | 0.190 |
Why?
|
Drug Combinations | 4 | 2023 | 224 | 0.190 |
Why?
|
High-Frequency Ventilation | 1 | 2000 | 9 | 0.190 |
Why?
|
Patient Advocacy | 3 | 2018 | 49 | 0.190 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2021 | 48 | 0.190 |
Why?
|
Food | 1 | 2021 | 86 | 0.190 |
Why?
|
Patient Satisfaction | 2 | 2016 | 455 | 0.190 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2015 | 592 | 0.190 |
Why?
|
Urban Health | 5 | 2011 | 55 | 0.190 |
Why?
|
Pyrazoles | 1 | 2021 | 153 | 0.190 |
Why?
|
Genetic Predisposition to Disease | 3 | 2019 | 2271 | 0.190 |
Why?
|
Status Asthmaticus | 1 | 2020 | 9 | 0.190 |
Why?
|
International Cooperation | 1 | 2020 | 127 | 0.180 |
Why?
|
Sepsis | 1 | 2004 | 306 | 0.180 |
Why?
|
Macrolides | 2 | 2017 | 31 | 0.180 |
Why?
|
Animals | 16 | 2015 | 26582 | 0.180 |
Why?
|
Bronchi | 1 | 2021 | 229 | 0.180 |
Why?
|
Incidence | 4 | 2012 | 1577 | 0.180 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2021 | 241 | 0.180 |
Why?
|
Wearable Electronic Devices | 1 | 2020 | 23 | 0.180 |
Why?
|
Proportional Hazards Models | 5 | 2019 | 859 | 0.180 |
Why?
|
Prescription Drug Overuse | 1 | 2019 | 2 | 0.180 |
Why?
|
Mometasone Furoate | 1 | 2019 | 18 | 0.180 |
Why?
|
Muscle, Smooth | 1 | 2021 | 354 | 0.170 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 217 | 0.170 |
Why?
|
Treatment Adherence and Compliance | 1 | 2019 | 5 | 0.170 |
Why?
|
Dose-Response Relationship, Drug | 6 | 2021 | 1961 | 0.170 |
Why?
|
Sirolimus | 2 | 2010 | 169 | 0.170 |
Why?
|
DNA, Mitochondrial | 1 | 2020 | 183 | 0.170 |
Why?
|
Self Efficacy | 3 | 2019 | 53 | 0.170 |
Why?
|
Costs and Cost Analysis | 1 | 2019 | 153 | 0.170 |
Why?
|
Lung Diseases, Interstitial | 2 | 2020 | 235 | 0.170 |
Why?
|
Anxiety | 4 | 2022 | 287 | 0.170 |
Why?
|
Arthroscopy | 1 | 1999 | 94 | 0.170 |
Why?
|
Deprescriptions | 1 | 2018 | 5 | 0.170 |
Why?
|
Consensus | 1 | 2020 | 335 | 0.170 |
Why?
|
Interdisciplinary Studies | 1 | 2018 | 20 | 0.170 |
Why?
|
Thrombosis | 1 | 2021 | 296 | 0.170 |
Why?
|
Immunosuppressive Agents | 3 | 2010 | 977 | 0.170 |
Why?
|
Hand | 1 | 1999 | 130 | 0.170 |
Why?
|
Amino Acids | 1 | 2019 | 252 | 0.160 |
Why?
|
Health Policy | 2 | 2018 | 180 | 0.160 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2018 | 56 | 0.160 |
Why?
|
Communication | 1 | 2021 | 441 | 0.160 |
Why?
|
Calcitonin | 1 | 2017 | 38 | 0.160 |
Why?
|
Arthritis, Rheumatoid | 1 | 1999 | 166 | 0.160 |
Why?
|
Gene Expression | 2 | 2021 | 1284 | 0.160 |
Why?
|
Global Health | 1 | 2019 | 193 | 0.160 |
Why?
|
Sensitivity and Specificity | 6 | 2016 | 1991 | 0.160 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2018 | 110 | 0.160 |
Why?
|
Predictive Value of Tests | 4 | 2014 | 1673 | 0.150 |
Why?
|
Osteoarthritis | 1 | 1998 | 73 | 0.150 |
Why?
|
Vitamin D | 1 | 2020 | 261 | 0.150 |
Why?
|
History, 21st Century | 1 | 2018 | 175 | 0.150 |
Why?
|
Betacoronavirus | 1 | 2020 | 258 | 0.150 |
Why?
|
Drug Prescriptions | 1 | 2018 | 141 | 0.150 |
Why?
|
PTEN Phosphohydrolase | 2 | 2010 | 128 | 0.150 |
Why?
|
Bacteria | 1 | 2021 | 447 | 0.150 |
Why?
|
Self-Management | 1 | 2017 | 29 | 0.150 |
Why?
|
Tetracyclines | 1 | 2016 | 4 | 0.150 |
Why?
|
Surgery Department, Hospital | 1 | 1997 | 42 | 0.150 |
Why?
|
New England | 1 | 2016 | 10 | 0.150 |
Why?
|
Patient Selection | 1 | 2021 | 685 | 0.150 |
Why?
|
Southeastern United States | 1 | 2016 | 8 | 0.150 |
Why?
|
History, 20th Century | 1 | 2018 | 312 | 0.150 |
Why?
|
Long QT Syndrome | 1 | 2016 | 34 | 0.140 |
Why?
|
Self Administration | 2 | 2009 | 73 | 0.140 |
Why?
|
Cephalosporins | 1 | 2016 | 24 | 0.140 |
Why?
|
Synthetic Biology | 1 | 2016 | 15 | 0.140 |
Why?
|
Inappropriate Prescribing | 1 | 2016 | 18 | 0.140 |
Why?
|
Biological Products | 1 | 2018 | 143 | 0.140 |
Why?
|
Administration, Oral | 4 | 2020 | 684 | 0.140 |
Why?
|
Respiration, Artificial | 4 | 2011 | 334 | 0.140 |
Why?
|
Public Policy | 1 | 2016 | 52 | 0.140 |
Why?
|
Decision Support Techniques | 1 | 2018 | 160 | 0.140 |
Why?
|
Quinolones | 1 | 2016 | 60 | 0.140 |
Why?
|
Intention | 1 | 2016 | 51 | 0.140 |
Why?
|
Peptide Fragments | 1 | 2018 | 460 | 0.140 |
Why?
|
Nonlinear Dynamics | 1 | 2016 | 73 | 0.140 |
Why?
|
Equipment Failure Analysis | 1 | 2016 | 90 | 0.140 |
Why?
|
Breast Neoplasms, Male | 1 | 1996 | 30 | 0.140 |
Why?
|
Checklist | 1 | 2016 | 57 | 0.140 |
Why?
|
Quality Improvement | 2 | 2017 | 428 | 0.130 |
Why?
|
Research Report | 1 | 2015 | 44 | 0.130 |
Why?
|
Orthopedics | 1 | 1997 | 124 | 0.130 |
Why?
|
Immunotherapy | 1 | 2020 | 629 | 0.130 |
Why?
|
Clinical Competence | 2 | 2014 | 751 | 0.130 |
Why?
|
Fatigue | 3 | 2023 | 174 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2017 | 425 | 0.130 |
Why?
|
Equipment Design | 1 | 2016 | 406 | 0.130 |
Why?
|
Attitude of Health Personnel | 2 | 2015 | 636 | 0.130 |
Why?
|
Metabolome | 1 | 2015 | 47 | 0.130 |
Why?
|
Kinetics | 2 | 2011 | 1513 | 0.130 |
Why?
|
Recovery of Function | 2 | 2014 | 272 | 0.130 |
Why?
|
alpha-N-Acetylgalactosaminidase | 1 | 2014 | 4 | 0.130 |
Why?
|
Cognition Disorders | 2 | 2013 | 236 | 0.130 |
Why?
|
Fractures, Bone | 2 | 2000 | 131 | 0.130 |
Why?
|
Pregnenediones | 1 | 2014 | 8 | 0.120 |
Why?
|
Fatty Acid Desaturases | 1 | 2014 | 17 | 0.120 |
Why?
|
Independent Living | 1 | 2014 | 18 | 0.120 |
Why?
|
Organizational Policy | 2 | 2016 | 55 | 0.120 |
Why?
|
Computer Communication Networks | 1 | 2014 | 23 | 0.120 |
Why?
|
Personnel Selection | 1 | 2015 | 59 | 0.120 |
Why?
|
Cross-Over Studies | 3 | 2020 | 399 | 0.120 |
Why?
|
Neoplasm Proteins | 1 | 2018 | 532 | 0.120 |
Why?
|
Cholecalciferol | 1 | 2014 | 35 | 0.120 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 1996 | 151 | 0.120 |
Why?
|
Monitoring, Ambulatory | 1 | 2014 | 32 | 0.120 |
Why?
|
Minority Health | 1 | 2013 | 10 | 0.120 |
Why?
|
Observation | 2 | 2011 | 37 | 0.120 |
Why?
|
Graft Rejection | 4 | 2010 | 1065 | 0.120 |
Why?
|
Pain Measurement | 3 | 2014 | 321 | 0.120 |
Why?
|
Feasibility Studies | 2 | 2013 | 751 | 0.120 |
Why?
|
Cell Phone | 1 | 2014 | 37 | 0.120 |
Why?
|
Stroke | 1 | 2023 | 965 | 0.120 |
Why?
|
Decision Making | 2 | 2011 | 642 | 0.120 |
Why?
|
Baltimore | 4 | 2006 | 36 | 0.120 |
Why?
|
Antineoplastic Agents | 3 | 2015 | 2360 | 0.120 |
Why?
|
Patients | 2 | 2016 | 100 | 0.120 |
Why?
|
Vitamins | 1 | 2014 | 81 | 0.120 |
Why?
|
Pharmacy Service, Hospital | 1 | 2013 | 9 | 0.120 |
Why?
|
Gait | 1 | 2014 | 80 | 0.120 |
Why?
|
Physicians | 2 | 2015 | 673 | 0.120 |
Why?
|
Survival Analysis | 5 | 2011 | 1538 | 0.120 |
Why?
|
South Australia | 4 | 2000 | 5 | 0.120 |
Why?
|
Hospitalists | 1 | 2015 | 131 | 0.120 |
Why?
|
Medical Order Entry Systems | 1 | 2013 | 25 | 0.120 |
Why?
|
Program Development | 1 | 2014 | 124 | 0.110 |
Why?
|
Lymphoma, B-Cell | 1 | 1994 | 103 | 0.110 |
Why?
|
Sleep Apnea Syndromes | 2 | 2017 | 103 | 0.110 |
Why?
|
Inflammation | 1 | 2019 | 920 | 0.110 |
Why?
|
Azathioprine | 2 | 2010 | 125 | 0.110 |
Why?
|
Lung Diseases, Obstructive | 1 | 2012 | 19 | 0.110 |
Why?
|
HLA-G Antigens | 1 | 2013 | 52 | 0.110 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2016 | 508 | 0.110 |
Why?
|
Faculty, Medical | 1 | 2015 | 178 | 0.110 |
Why?
|
Glucose | 1 | 2016 | 638 | 0.110 |
Why?
|
Heart Diseases | 1 | 2015 | 290 | 0.110 |
Why?
|
Idiopathic Interstitial Pneumonias | 1 | 2012 | 28 | 0.110 |
Why?
|
Guidelines as Topic | 1 | 2013 | 162 | 0.110 |
Why?
|
Saccharomyces cerevisiae | 1 | 2016 | 434 | 0.110 |
Why?
|
Ethanolamines | 2 | 2023 | 32 | 0.110 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2013 | 141 | 0.110 |
Why?
|
Postoperative Complications | 1 | 2002 | 2207 | 0.110 |
Why?
|
Protein Interaction Maps | 1 | 2012 | 48 | 0.110 |
Why?
|
Clinical Protocols | 2 | 2021 | 156 | 0.110 |
Why?
|
Tacrolimus | 2 | 2010 | 373 | 0.110 |
Why?
|
T-Lymphocytes | 3 | 1994 | 1195 | 0.110 |
Why?
|
Cardiovascular Diseases | 2 | 2021 | 827 | 0.100 |
Why?
|
Intermediate Care Facilities | 1 | 2011 | 2 | 0.100 |
Why?
|
Connective Tissue Diseases | 1 | 2012 | 67 | 0.100 |
Why?
|
ROC Curve | 3 | 2017 | 752 | 0.100 |
Why?
|
Pneumonia | 1 | 2013 | 179 | 0.100 |
Why?
|
Positive-Pressure Respiration | 1 | 2011 | 41 | 0.100 |
Why?
|
Substrate Specificity | 1 | 2012 | 347 | 0.100 |
Why?
|
Residence Characteristics | 3 | 2021 | 197 | 0.100 |
Why?
|
Policy Making | 1 | 2011 | 62 | 0.100 |
Why?
|
Tidal Volume | 2 | 2008 | 53 | 0.100 |
Why?
|
Medical Records | 1 | 2012 | 119 | 0.100 |
Why?
|
Sleep | 3 | 2020 | 444 | 0.100 |
Why?
|
Mathematical Concepts | 1 | 2011 | 18 | 0.100 |
Why?
|
Health Care Coalitions | 1 | 2011 | 9 | 0.100 |
Why?
|
Community Health Planning | 1 | 2011 | 21 | 0.100 |
Why?
|
Membrane Proteins | 1 | 2018 | 1196 | 0.100 |
Why?
|
Hernia, Hiatal | 1 | 2011 | 30 | 0.100 |
Why?
|
Internal Medicine | 1 | 2015 | 347 | 0.100 |
Why?
|
Range of Motion, Articular | 2 | 2003 | 154 | 0.100 |
Why?
|
Anticarcinogenic Agents | 1 | 2011 | 70 | 0.100 |
Why?
|
Hypertension | 2 | 2012 | 1141 | 0.100 |
Why?
|
Skilled Nursing Facilities | 1 | 2011 | 41 | 0.100 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 1384 | 0.100 |
Why?
|
Morbidity | 2 | 2022 | 148 | 0.100 |
Why?
|
Multicenter Studies as Topic | 2 | 2023 | 159 | 0.100 |
Why?
|
Receptors, Cyclic AMP | 1 | 2010 | 2 | 0.100 |
Why?
|
Neutrophils | 2 | 2017 | 307 | 0.100 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2010 | 3 | 0.100 |
Why?
|
Phosphatidylinositol 4,5-Diphosphate | 1 | 2010 | 10 | 0.090 |
Why?
|
Diglycerides | 1 | 2010 | 22 | 0.090 |
Why?
|
Type C Phospholipases | 1 | 2010 | 28 | 0.090 |
Why?
|
Phosphatidylinositol Phosphates | 1 | 2010 | 15 | 0.090 |
Why?
|
Models, Educational | 1 | 2010 | 50 | 0.090 |
Why?
|
Attitude to Health | 2 | 2004 | 220 | 0.090 |
Why?
|
Peptide Chain Termination, Translational | 1 | 2010 | 6 | 0.090 |
Why?
|
Immunoglobulin G | 2 | 2023 | 456 | 0.090 |
Why?
|
Body Mass Index | 4 | 2020 | 770 | 0.090 |
Why?
|
Aminopyridines | 2 | 2023 | 38 | 0.090 |
Why?
|
Biological Variation, Population | 2 | 2020 | 8 | 0.090 |
Why?
|
Thionucleotides | 1 | 2010 | 56 | 0.090 |
Why?
|
Pseudopodia | 1 | 2010 | 35 | 0.090 |
Why?
|
Psychometrics | 3 | 2021 | 327 | 0.090 |
Why?
|
Radiography | 3 | 2006 | 813 | 0.090 |
Why?
|
Reimbursement, Incentive | 1 | 2010 | 37 | 0.090 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 178 | 0.090 |
Why?
|
Blood Glucose | 2 | 2012 | 873 | 0.090 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2010 | 66 | 0.090 |
Why?
|
Scopolamine Derivatives | 1 | 2009 | 4 | 0.090 |
Why?
|
Tibia | 2 | 2004 | 82 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2018 | 2357 | 0.090 |
Why?
|
Leukotriene Antagonists | 1 | 2009 | 25 | 0.090 |
Why?
|
Albuterol | 2 | 2020 | 35 | 0.090 |
Why?
|
Cockroaches | 2 | 2006 | 10 | 0.090 |
Why?
|
Skin Tests | 2 | 2006 | 44 | 0.090 |
Why?
|
Child Abuse | 1 | 1990 | 78 | 0.090 |
Why?
|
Cyclic AMP | 1 | 2010 | 273 | 0.090 |
Why?
|
Heart Failure | 2 | 2016 | 1204 | 0.090 |
Why?
|
Pharmacogenetics | 1 | 2013 | 434 | 0.090 |
Why?
|
Physicians, Family | 1 | 2009 | 40 | 0.090 |
Why?
|
Risk Reduction Behavior | 1 | 2010 | 98 | 0.090 |
Why?
|
Phenotype | 3 | 2023 | 2378 | 0.090 |
Why?
|
Physician-Patient Relations | 2 | 2007 | 610 | 0.090 |
Why?
|
Hospital Charges | 2 | 2006 | 29 | 0.090 |
Why?
|
Systems Analysis | 1 | 2009 | 17 | 0.090 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2011 | 165 | 0.080 |
Why?
|
Medicaid | 2 | 2024 | 217 | 0.080 |
Why?
|
Inhalation | 1 | 2008 | 31 | 0.080 |
Why?
|
Veterans | 1 | 2009 | 72 | 0.080 |
Why?
|
Disabled Persons | 2 | 2000 | 67 | 0.080 |
Why?
|
Diagnosis, Differential | 3 | 2012 | 1565 | 0.080 |
Why?
|
Counseling | 1 | 2010 | 145 | 0.080 |
Why?
|
Actin Cytoskeleton | 1 | 2010 | 192 | 0.080 |
Why?
|
Europe | 2 | 2020 | 309 | 0.080 |
Why?
|
MicroRNAs | 1 | 2013 | 534 | 0.080 |
Why?
|
Omalizumab | 1 | 2007 | 8 | 0.080 |
Why?
|
Managed Care Programs | 3 | 2004 | 42 | 0.080 |
Why?
|
Insulin Resistance | 1 | 2010 | 377 | 0.080 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2007 | 44 | 0.080 |
Why?
|
Leukemia, Hairy Cell | 1 | 1988 | 186 | 0.080 |
Why?
|
Cell Division | 1 | 2009 | 696 | 0.080 |
Why?
|
Combined Modality Therapy | 2 | 2022 | 1686 | 0.080 |
Why?
|
Parents | 1 | 1990 | 272 | 0.080 |
Why?
|
Sex Distribution | 2 | 2012 | 173 | 0.080 |
Why?
|
Ethics, Research | 1 | 2007 | 52 | 0.070 |
Why?
|
Motivation | 1 | 2010 | 287 | 0.070 |
Why?
|
Congresses as Topic | 2 | 2019 | 116 | 0.070 |
Why?
|
Scleroderma, Limited | 1 | 2006 | 1 | 0.070 |
Why?
|
Pregnancy | 3 | 2021 | 2894 | 0.070 |
Why?
|
Outpatients | 2 | 2022 | 94 | 0.070 |
Why?
|
Breath Tests | 2 | 2023 | 55 | 0.070 |
Why?
|
Vitamin K | 1 | 2006 | 25 | 0.070 |
Why?
|
Adaptation, Physiological | 1 | 2009 | 306 | 0.070 |
Why?
|
Genome-Wide Association Study | 1 | 2014 | 1621 | 0.070 |
Why?
|
Cystic Fibrosis | 1 | 2007 | 112 | 0.070 |
Why?
|
Argentina | 1 | 2006 | 13 | 0.070 |
Why?
|
Waist Circumference | 2 | 2018 | 20 | 0.070 |
Why?
|
Prognosis | 3 | 2018 | 3679 | 0.070 |
Why?
|
Splenic Neoplasms | 2 | 1998 | 16 | 0.070 |
Why?
|
Treatment Failure | 2 | 2019 | 285 | 0.070 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 1988 | 206 | 0.070 |
Why?
|
Insect Control | 1 | 2005 | 4 | 0.070 |
Why?
|
Genotype | 3 | 2018 | 1851 | 0.070 |
Why?
|
Filtration | 1 | 2005 | 25 | 0.070 |
Why?
|
United States Environmental Protection Agency | 1 | 2005 | 5 | 0.070 |
Why?
|
Survival Rate | 2 | 2009 | 1863 | 0.070 |
Why?
|
Bedding and Linens | 1 | 2005 | 12 | 0.070 |
Why?
|
Body Temperature | 1 | 2006 | 124 | 0.070 |
Why?
|
Axilla | 1 | 2006 | 99 | 0.070 |
Why?
|
Community-Acquired Infections | 1 | 2006 | 63 | 0.070 |
Why?
|
Quantitative Trait Loci | 2 | 2021 | 576 | 0.070 |
Why?
|
Ambulatory Care | 2 | 2004 | 181 | 0.070 |
Why?
|
Internship and Residency | 1 | 2015 | 1004 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2006 | 916 | 0.070 |
Why?
|
Scleroderma, Systemic | 1 | 2005 | 43 | 0.070 |
Why?
|
Mice | 4 | 2006 | 11352 | 0.070 |
Why?
|
Health Education | 1 | 2005 | 101 | 0.060 |
Why?
|
Bone Cements | 1 | 2004 | 9 | 0.060 |
Why?
|
Knee Prosthesis | 1 | 2004 | 33 | 0.060 |
Why?
|
Models, Genetic | 1 | 2010 | 926 | 0.060 |
Why?
|
Referral and Consultation | 2 | 2009 | 328 | 0.060 |
Why?
|
Vascular Resistance | 1 | 2004 | 102 | 0.060 |
Why?
|
Needs Assessment | 1 | 2005 | 154 | 0.060 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2007 | 930 | 0.060 |
Why?
|
Infant, Newborn | 2 | 2006 | 2379 | 0.060 |
Why?
|
Mental Health | 2 | 2016 | 162 | 0.060 |
Why?
|
Enzyme Activation | 1 | 2005 | 692 | 0.060 |
Why?
|
Cardiac Output | 1 | 2004 | 156 | 0.060 |
Why?
|
Blood Pressure | 2 | 2012 | 1143 | 0.060 |
Why?
|
Pulmonary Ventilation | 1 | 2003 | 32 | 0.060 |
Why?
|
APACHE | 1 | 2003 | 21 | 0.060 |
Why?
|
Educational Measurement | 1 | 2005 | 225 | 0.060 |
Why?
|
Bronchoalveolar Lavage | 1 | 2023 | 26 | 0.060 |
Why?
|
Immunologic Tests | 1 | 2023 | 6 | 0.060 |
Why?
|
Polysomnography | 2 | 2020 | 151 | 0.060 |
Why?
|
Sulfonamides | 1 | 2005 | 300 | 0.060 |
Why?
|
Pneumococcal Vaccines | 1 | 2023 | 28 | 0.060 |
Why?
|
Parenteral Nutrition | 1 | 2003 | 60 | 0.060 |
Why?
|
Soot | 1 | 2022 | 2 | 0.060 |
Why?
|
Mathematical Computing | 1 | 2003 | 21 | 0.060 |
Why?
|
Cotinine | 1 | 2022 | 12 | 0.060 |
Why?
|
Ventricular Function, Right | 1 | 2004 | 142 | 0.060 |
Why?
|
Nutritional Status | 1 | 2003 | 83 | 0.060 |
Why?
|
Streptococcus pneumoniae | 1 | 2023 | 48 | 0.060 |
Why?
|
Transportation | 1 | 2022 | 18 | 0.060 |
Why?
|
Insurance, Health | 1 | 2024 | 160 | 0.060 |
Why?
|
Glycopyrrolate | 1 | 2022 | 4 | 0.060 |
Why?
|
Mothers | 1 | 2004 | 141 | 0.060 |
Why?
|
Antibodies, Bacterial | 1 | 2023 | 95 | 0.060 |
Why?
|
Life Style | 1 | 2023 | 189 | 0.060 |
Why?
|
Depressive Disorder | 1 | 2004 | 218 | 0.060 |
Why?
|
Autoantibodies | 1 | 2024 | 267 | 0.050 |
Why?
|
Gene Expression Regulation | 3 | 2018 | 1920 | 0.050 |
Why?
|
Immunologic Factors | 1 | 2024 | 170 | 0.050 |
Why?
|
Health Services for the Aged | 1 | 2002 | 27 | 0.050 |
Why?
|
Carbon | 1 | 2022 | 80 | 0.050 |
Why?
|
Nitric Oxide | 1 | 2023 | 278 | 0.050 |
Why?
|
Hemiterpenes | 1 | 2001 | 6 | 0.050 |
Why?
|
Weight Loss | 1 | 2023 | 229 | 0.050 |
Why?
|
Particulate Matter | 1 | 2022 | 79 | 0.050 |
Why?
|
Early Termination of Clinical Trials | 1 | 2021 | 20 | 0.050 |
Why?
|
Patient Acuity | 1 | 2022 | 32 | 0.050 |
Why?
|
Breast Neoplasms | 1 | 1996 | 2903 | 0.050 |
Why?
|
Antilymphocyte Serum | 1 | 2001 | 71 | 0.050 |
Why?
|
Muromonab-CD3 | 1 | 2001 | 69 | 0.050 |
Why?
|
Asia | 1 | 2001 | 95 | 0.050 |
Why?
|
Biological Transport | 2 | 2013 | 396 | 0.050 |
Why?
|
Poverty Areas | 3 | 2006 | 37 | 0.050 |
Why?
|
Ligands | 1 | 2003 | 433 | 0.050 |
Why?
|
Bone Density | 1 | 2002 | 209 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2024 | 238 | 0.050 |
Why?
|
Academies and Institutes | 1 | 2021 | 31 | 0.050 |
Why?
|
Early Diagnosis | 1 | 2022 | 131 | 0.050 |
Why?
|
Fibrinolytic Agents | 1 | 2003 | 202 | 0.050 |
Why?
|
Vaccination | 1 | 2023 | 254 | 0.050 |
Why?
|
Prescriptions | 1 | 2021 | 21 | 0.050 |
Why?
|
Residential Facilities | 1 | 2000 | 3 | 0.050 |
Why?
|
Lymphoma | 1 | 1983 | 262 | 0.050 |
Why?
|
Pituitary Neoplasms | 1 | 2001 | 62 | 0.050 |
Why?
|
Students | 1 | 2022 | 147 | 0.050 |
Why?
|
Antihypertensive Agents | 1 | 2005 | 521 | 0.050 |
Why?
|
Emotions | 1 | 2004 | 341 | 0.050 |
Why?
|
Expiratory Reserve Volume | 1 | 2000 | 1 | 0.050 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 176 | 0.050 |
Why?
|
Receptors, Thyroid Hormone | 1 | 2001 | 159 | 0.050 |
Why?
|
Pulmonary Gas Exchange | 1 | 2000 | 31 | 0.050 |
Why?
|
Anxiety Disorders | 1 | 2022 | 148 | 0.050 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2021 | 121 | 0.050 |
Why?
|
Respiratory Therapy | 1 | 2020 | 14 | 0.050 |
Why?
|
Fibula | 1 | 2000 | 32 | 0.050 |
Why?
|
Allied Health Personnel | 1 | 2020 | 19 | 0.050 |
Why?
|
Ankle Injuries | 1 | 2000 | 30 | 0.050 |
Why?
|
Poverty | 1 | 2022 | 173 | 0.050 |
Why?
|
Thyrotropin | 1 | 2001 | 280 | 0.050 |
Why?
|
Healthy Volunteers | 1 | 2021 | 143 | 0.050 |
Why?
|
Alcoholic Intoxication | 1 | 2000 | 31 | 0.050 |
Why?
|
Bone Screws | 1 | 2000 | 44 | 0.050 |
Why?
|
Hip Fractures | 1 | 2000 | 45 | 0.050 |
Why?
|
Breast Feeding | 1 | 2021 | 91 | 0.050 |
Why?
|
Molecular Epidemiology | 1 | 2020 | 53 | 0.050 |
Why?
|
Alternative Splicing | 1 | 2001 | 201 | 0.050 |
Why?
|
Geography | 1 | 2021 | 223 | 0.050 |
Why?
|
Residual Volume | 1 | 2019 | 1 | 0.050 |
Why?
|
Total Lung Capacity | 1 | 2019 | 5 | 0.050 |
Why?
|
Fracture Fixation, Internal | 1 | 2000 | 66 | 0.050 |
Why?
|
Occupational Therapy | 1 | 1999 | 16 | 0.040 |
Why?
|
Occupations | 1 | 1999 | 26 | 0.040 |
Why?
|
Isoleucine | 1 | 2019 | 17 | 0.040 |
Why?
|
Proton Magnetic Resonance Spectroscopy | 1 | 2019 | 12 | 0.040 |
Why?
|
Research | 1 | 2021 | 253 | 0.040 |
Why?
|
Leucine | 1 | 2019 | 67 | 0.040 |
Why?
|
Macrophages | 1 | 2022 | 554 | 0.040 |
Why?
|
Valine | 1 | 2019 | 69 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 20 | 0.040 |
Why?
|
Metabolomics | 1 | 2019 | 68 | 0.040 |
Why?
|
Tryptophan | 1 | 2019 | 90 | 0.040 |
Why?
|
Fibrinogen | 1 | 2019 | 56 | 0.040 |
Why?
|
Reminder Systems | 1 | 2018 | 16 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 43 | 0.040 |
Why?
|
Culturally Competent Care | 1 | 2018 | 12 | 0.040 |
Why?
|
Orthopedic Procedures | 1 | 2000 | 128 | 0.040 |
Why?
|
Functional Laterality | 1 | 1999 | 201 | 0.040 |
Why?
|
Motivational Interviewing | 1 | 2018 | 18 | 0.040 |
Why?
|
Propensity Score | 1 | 2019 | 136 | 0.040 |
Why?
|
Problem Solving | 1 | 2018 | 54 | 0.040 |
Why?
|
Italy | 1 | 2018 | 106 | 0.040 |
Why?
|
Self Concept | 1 | 2019 | 133 | 0.040 |
Why?
|
Peak Expiratory Flow Rate | 1 | 2018 | 10 | 0.040 |
Why?
|
Self-Injurious Behavior | 1 | 2000 | 105 | 0.040 |
Why?
|
Hospital Costs | 1 | 2019 | 105 | 0.040 |
Why?
|
Growth | 1 | 2018 | 43 | 0.040 |
Why?
|
Prednisone | 2 | 2010 | 258 | 0.040 |
Why?
|
Risk | 2 | 2014 | 674 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 127 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 1983 | 546 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2019 | 190 | 0.040 |
Why?
|
Phosphodiesterase 4 Inhibitors | 1 | 2017 | 3 | 0.040 |
Why?
|
Diarrhea | 1 | 2019 | 182 | 0.040 |
Why?
|
Aftercare | 1 | 2019 | 85 | 0.040 |
Why?
|
Cyclopropanes | 1 | 2017 | 25 | 0.040 |
Why?
|
Nasal Polyps | 1 | 2018 | 58 | 0.040 |
Why?
|
Monitoring, Physiologic | 1 | 2019 | 268 | 0.040 |
Why?
|
Fluoroquinolones | 1 | 2017 | 22 | 0.040 |
Why?
|
Apoptosis | 2 | 2015 | 1683 | 0.040 |
Why?
|
CpG Islands | 1 | 2018 | 151 | 0.040 |
Why?
|
Interleukin-8 | 1 | 2017 | 86 | 0.040 |
Why?
|
Preoperative Care | 1 | 2000 | 397 | 0.040 |
Why?
|
Arthroplasty | 1 | 1997 | 27 | 0.040 |
Why?
|
Immunophenotyping | 2 | 1994 | 211 | 0.040 |
Why?
|
Biopsy | 2 | 2013 | 1163 | 0.040 |
Why?
|
Noninvasive Ventilation | 1 | 2017 | 24 | 0.040 |
Why?
|
Pain | 1 | 1999 | 391 | 0.040 |
Why?
|
Family | 1 | 2018 | 311 | 0.040 |
Why?
|
Bronchiolitis Obliterans | 2 | 2010 | 31 | 0.040 |
Why?
|
Interleukin-15 | 1 | 2017 | 72 | 0.040 |
Why?
|
Evidence-Based Practice | 1 | 2016 | 45 | 0.040 |
Why?
|
Heart Transplantation | 1 | 2002 | 705 | 0.040 |
Why?
|
Community-Based Participatory Research | 1 | 2016 | 36 | 0.040 |
Why?
|
Respiratory Sounds | 1 | 2016 | 33 | 0.040 |
Why?
|
Benzamides | 1 | 2017 | 229 | 0.040 |
Why?
|
Community Health Workers | 1 | 2016 | 26 | 0.040 |
Why?
|
Cough | 1 | 2016 | 54 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2021 | 1805 | 0.040 |
Why?
|
Diabetes Mellitus | 2 | 2014 | 806 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2001 | 1197 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1998 | 261 | 0.030 |
Why?
|
Polymerase Chain Reaction | 2 | 1994 | 927 | 0.030 |
Why?
|
B-Lymphocytes | 2 | 1994 | 724 | 0.030 |
Why?
|
Cardiac Rehabilitation | 1 | 2014 | 4 | 0.030 |
Why?
|
Lymphomatoid Granulomatosis | 1 | 1994 | 5 | 0.030 |
Why?
|
Muscle Strength | 1 | 2014 | 31 | 0.030 |
Why?
|
Costa Rica | 1 | 2014 | 15 | 0.030 |
Why?
|
Qualitative Research | 1 | 2016 | 256 | 0.030 |
Why?
|
Computer Security | 1 | 2014 | 16 | 0.030 |
Why?
|
Accidental Falls | 1 | 2014 | 50 | 0.030 |
Why?
|
Medical Record Linkage | 1 | 2014 | 17 | 0.030 |
Why?
|
Drug Discovery | 1 | 2015 | 103 | 0.030 |
Why?
|
Electrocardiography | 1 | 2016 | 478 | 0.030 |
Why?
|
Support Vector Machine | 1 | 2014 | 25 | 0.030 |
Why?
|
Health Planning Guidelines | 1 | 2014 | 24 | 0.030 |
Why?
|
Genetic Variation | 1 | 2021 | 1351 | 0.030 |
Why?
|
Confidentiality | 1 | 2014 | 78 | 0.030 |
Why?
|
Hemangiosarcoma | 1 | 1993 | 17 | 0.030 |
Why?
|
Accelerometry | 1 | 2014 | 36 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 1994 | 114 | 0.030 |
Why?
|
Disability Evaluation | 1 | 2014 | 136 | 0.030 |
Why?
|
Blood Volume | 1 | 1993 | 51 | 0.030 |
Why?
|
Exercise Test | 1 | 2014 | 164 | 0.030 |
Why?
|
Base Sequence | 2 | 1994 | 2330 | 0.030 |
Why?
|
Models, Animal | 2 | 2005 | 263 | 0.030 |
Why?
|
DNA Methylation | 1 | 2018 | 628 | 0.030 |
Why?
|
Blood Platelets | 1 | 1993 | 149 | 0.030 |
Why?
|
Fractures, Stress | 1 | 1992 | 10 | 0.030 |
Why?
|
Muscle Weakness | 1 | 2013 | 61 | 0.030 |
Why?
|
Maternal Exposure | 1 | 2013 | 57 | 0.030 |
Why?
|
Tibial Fractures | 1 | 1992 | 39 | 0.030 |
Why?
|
Oximetry | 1 | 2013 | 84 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 1994 | 3030 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 1993 | 183 | 0.030 |
Why?
|
Transcriptome | 1 | 2017 | 580 | 0.030 |
Why?
|
Intracellular Space | 1 | 2011 | 38 | 0.030 |
Why?
|
Myocardial Ischemia | 1 | 2013 | 162 | 0.030 |
Why?
|
Age Distribution | 1 | 2012 | 204 | 0.030 |
Why?
|
Osteoporosis | 1 | 2013 | 121 | 0.030 |
Why?
|
Sampling Studies | 1 | 2011 | 70 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2012 | 114 | 0.030 |
Why?
|
Injections | 1 | 2011 | 109 | 0.030 |
Why?
|
Dementia | 1 | 2013 | 187 | 0.030 |
Why?
|
Extracellular Space | 1 | 2011 | 90 | 0.030 |
Why?
|
Community Participation | 1 | 2011 | 36 | 0.030 |
Why?
|
Manometry | 1 | 2011 | 43 | 0.030 |
Why?
|
Cell Count | 1 | 2011 | 195 | 0.030 |
Why?
|
Neuropsychological Tests | 1 | 2013 | 502 | 0.030 |
Why?
|
Community Pharmacy Services | 1 | 2011 | 5 | 0.020 |
Why?
|
Health Plan Implementation | 1 | 2011 | 56 | 0.020 |
Why?
|
Social Behavior | 1 | 2014 | 294 | 0.020 |
Why?
|
Drug Utilization Review | 1 | 2011 | 14 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 229 | 0.020 |
Why?
|
Substance-Related Disorders | 1 | 2014 | 394 | 0.020 |
Why?
|
Doxorubicin | 1 | 2011 | 295 | 0.020 |
Why?
|
Catheter Ablation | 1 | 2012 | 233 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2011 | 493 | 0.020 |
Why?
|
Codon, Nonsense | 1 | 2010 | 41 | 0.020 |
Why?
|
gamma-Globulins | 1 | 1989 | 16 | 0.020 |
Why?
|
Red-Cell Aplasia, Pure | 1 | 1989 | 5 | 0.020 |
Why?
|
Survivors | 1 | 2011 | 226 | 0.020 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2009 | 37 | 0.020 |
Why?
|
Paclitaxel | 1 | 2011 | 460 | 0.020 |
Why?
|
Computational Biology | 1 | 2013 | 528 | 0.020 |
Why?
|
Gastroesophageal Reflux | 1 | 2011 | 117 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 1990 | 106 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 1990 | 157 | 0.020 |
Why?
|
Cisplatin | 1 | 2011 | 612 | 0.020 |
Why?
|
Social Environment | 1 | 1990 | 188 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 1994 | 1939 | 0.020 |
Why?
|
Public Health | 1 | 2010 | 129 | 0.020 |
Why?
|
Ventilators, Mechanical | 1 | 2008 | 33 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2010 | 144 | 0.020 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1989 | 136 | 0.020 |
Why?
|
Escherichia coli Proteins | 1 | 2010 | 179 | 0.020 |
Why?
|
Biomechanical Phenomena | 1 | 1990 | 457 | 0.020 |
Why?
|
Splenectomy | 1 | 1988 | 82 | 0.020 |
Why?
|
Cause of Death | 1 | 2009 | 277 | 0.020 |
Why?
|
Health Promotion | 1 | 2010 | 160 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 860 | 0.020 |
Why?
|
Family Practice | 1 | 2007 | 84 | 0.020 |
Why?
|
Directly Observed Therapy | 1 | 2006 | 5 | 0.020 |
Why?
|
Public Housing | 1 | 2006 | 7 | 0.020 |
Why?
|
MEDLINE | 1 | 2006 | 8 | 0.020 |
Why?
|
Escherichia coli | 1 | 2010 | 597 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2007 | 278 | 0.020 |
Why?
|
Health Surveys | 1 | 2007 | 239 | 0.020 |
Why?
|
Personality Inventory | 1 | 2006 | 108 | 0.020 |
Why?
|
Bone Marrow | 1 | 1988 | 435 | 0.020 |
Why?
|
Androstadienes | 1 | 2006 | 72 | 0.020 |
Why?
|
Exercise Tolerance | 1 | 2005 | 48 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2006 | 238 | 0.020 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2005 | 69 | 0.020 |
Why?
|
Particle Size | 1 | 2005 | 122 | 0.020 |
Why?
|
Polymethyl Methacrylate | 1 | 2004 | 12 | 0.020 |
Why?
|
Absenteeism | 1 | 2004 | 9 | 0.020 |
Why?
|
Critical Pathways | 1 | 2004 | 35 | 0.020 |
Why?
|
Pulmonary Artery | 1 | 2006 | 306 | 0.020 |
Why?
|
Maryland | 1 | 2004 | 35 | 0.020 |
Why?
|
Prosthesis Failure | 1 | 2004 | 111 | 0.020 |
Why?
|
Washington | 1 | 2004 | 48 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2004 | 251 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2010 | 1981 | 0.010 |
Why?
|
Seasons | 1 | 2005 | 223 | 0.010 |
Why?
|
Regression Analysis | 1 | 2005 | 596 | 0.010 |
Why?
|
Mice, Inbred DBA | 1 | 2003 | 148 | 0.010 |
Why?
|
Knee Joint | 1 | 2004 | 168 | 0.010 |
Why?
|
Acid Phosphatase | 1 | 1983 | 33 | 0.010 |
Why?
|
Swine | 1 | 2004 | 555 | 0.010 |
Why?
|
Lymphadenitis | 1 | 1983 | 6 | 0.010 |
Why?
|
Histiocytes | 1 | 1983 | 22 | 0.010 |
Why?
|
Mice, Inbred Strains | 1 | 2003 | 307 | 0.010 |
Why?
|
Sex Ratio | 1 | 1983 | 22 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 2004 | 989 | 0.010 |
Why?
|
Histocytochemistry | 1 | 1983 | 130 | 0.010 |
Why?
|
Arousal | 1 | 2003 | 170 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2004 | 912 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2003 | 364 | 0.010 |
Why?
|
Heparin | 1 | 2003 | 175 | 0.010 |
Why?
|
Ethane | 1 | 2001 | 2 | 0.010 |
Why?
|
Sulfur Oxides | 1 | 2001 | 4 | 0.010 |
Why?
|
Acetone | 1 | 2001 | 6 | 0.010 |
Why?
|
Pentanes | 1 | 2001 | 4 | 0.010 |
Why?
|
Hemodynamics | 1 | 2005 | 710 | 0.010 |
Why?
|
Butadienes | 1 | 2001 | 33 | 0.010 |
Why?
|
Two-Hybrid System Techniques | 1 | 2001 | 55 | 0.010 |
Why?
|
Opportunistic Infections | 1 | 2001 | 59 | 0.010 |
Why?
|
Hydrogen Sulfide | 1 | 2001 | 50 | 0.010 |
Why?
|
Home Care Services, Hospital-Based | 1 | 2000 | 10 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2001 | 268 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2001 | 270 | 0.010 |
Why?
|
Triiodothyronine | 1 | 2001 | 339 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2001 | 557 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 879 | 0.010 |
Why?
|
Adenoma | 1 | 2001 | 235 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 1989 | 2438 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2001 | 996 | 0.010 |
Why?
|
Lymph Nodes | 1 | 1983 | 533 | 0.010 |
Why?
|
Mutation | 1 | 2010 | 3968 | 0.010 |
Why?
|
Ultrasonography | 1 | 1998 | 695 | 0.010 |
Why?
|
Vasculitis | 1 | 1994 | 39 | 0.010 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 1994 | 131 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1994 | 303 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1994 | 307 | 0.010 |
Why?
|
Methods | 1 | 1993 | 152 | 0.010 |
Why?
|
Platelet Count | 1 | 1993 | 92 | 0.010 |
Why?
|
Gene Rearrangement | 1 | 1994 | 170 | 0.010 |
Why?
|
Technetium Tc 99m Medronate | 1 | 1992 | 10 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 1992 | 220 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1994 | 372 | 0.010 |
Why?
|
Anemia, Hemolytic | 1 | 1989 | 19 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 1989 | 244 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 1993 | 1753 | 0.010 |
Why?
|